Ascendis 製藥公司

SecurityASND / Ascendis Pharma A/S
InstitutionLindbrook Capital, Llc
Latest Disclosed Ownership284 shares
Latest Disclosed Value $ 44,264
Lindbrook Capital, Llc reports 2.07% decrease in ownership of ASND / Ascendis Pharma A/S

On May 5, 2025 - Lindbrook Capital, Llc filed a 13F-HR form disclosing ownership of 284 shares of Ascendis Pharma A/S (US:ASND) valued at $44,264 USD as of March 31, 2025. The entity filed a previous 13F-HR on February 6, 2025 disclosing 290 shares of Ascendis Pharma A/S. This represents a change in shares of -2.07% during the quarter. The current value of the position is $59,768 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-05-05 2025-03-31 13F ASCENDIS PHARMA A ADR 04351P101 284 -6 -2.07 44 12.82 0.0041
2025-02-06 2024-12-31 13F ASCENDIS PHARMA A ADR 04351P101 290 1 0.35 40 -9.30 0.0036
2024-11-01 2024-09-30 13F ASCENDIS PHARMA A ADR 04351P101 289 1 0.35 43 10.26 0.0038
2024-07-31 2024-06-30 13F ASCENDIS PHARMA A ADR 04351P101 288 -1 -0.35 39 -9.30 0.0037
2024-04-25 2024-03-31 13F ASCENDIS PHARMA A ADR 04351P101 289 1 0.35 44 19.44 0.0041
2024-02-01 2023-12-31 13F ASCENDIS PHARMA A ADR 04351P101 288 5 1.77 36 38.46 0.0036
2023-10-25 2023-09-30 13F ASCENDIS PHARMA A ADR 04351P101 283 -14 -4.71 26 0.00 0.0030
2023-07-31 2023-06-30 13F ASCENDIS PHARMA A ADR 04351P101 297 -157 -34.58 27 -45.83 0.0028
2023-04-26 2023-03-31 13F ASCENDIS PHARMA A ADR 04351P101 454 -80 -14.98 49 -26.15 0.0057
2023-01-25 2022-12-31 13F ASCENDIS PHARMA A ADR 04351P101 534 43 8.76 65 27.45 0.0080
2022-11-10 2022-09-30 13F ASCENDIS PHARMA A ADR 04351P101 491 -22 -4.29 51 6.25 0.0086
2022-08-01 2022-06-30 13F ASCENDIS PHARMA A ADR 04351P101 513 116 29.22 48 2.13 0.0079
2022-04-21 2022-03-31 13F ASCENDIS PHARMA A ADR 04351P101 397 -1 -0.25 47 -12.96 0.0073
2022-01-18 2021-12-31 13F ASCENDIS PHARMA A ADR 04351P101 398 -127 -24.19 54 -35.71 0.0082
2021-11-05 2021-09-30 13F ASCENDIS PHARMA A ADR 04351P101 525 -12 -2.23 84 18.31 0.0220
2021-07-27 2021-06-30 13F ASCENDIS PHARMA A ADR 04351P101 537 97 22.05 71 24.56 0.0159
2021-04-28 2021-03-31 13F ASCENDIS PHARMA A ADR 04351P101 440 28 6.80 57 -17.39 0.0128
2021-01-27 2020-12-31 13F ASCENDIS PHARMA A ADR 04351P101 412 3 0.73 69 9.52 0.0169
2020-11-03 2020-09-30 13F ASCENDIS PHARMA A ADR 04351P101 409 99 31.94 63 36.96 0.0173
2020-07-27 2020-06-30 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 310 -100 -24.39 46 0.00 0.0136
2020-04-22 2020-03-31 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 410 -542 -56.93 46 -65.15 0.0174
2020-01-27 2019-12-31 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 952 100 11.74 132 60.98 0.0460
2019-10-30 2019-09-30 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 852 387 83.23 82 54.72 0.0310
2019-07-24 2019-06-30 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 465 -200 -30.08 53 -32.05 0.0204
2019-04-23 2019-03-31 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 665 -200 -23.12 78 44.44 0.0311
2019-02-07 2018-12-31 13F ASCENDIS PHARMA A S SPONSORED ADR ADR 04351P101 865 865 54 0.0266
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.